A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Muscle-Invasive Bladder Cancer Patients after Partial Cystectomy
Table 1
Baseline demographical and clinicopathological characteristics of patients.
Characteristics
Total cohort N (%)
Development cohort N (%)
Validation cohort N (%)
value
Number of patients
866
608
258
Median age (25th–75th percentile)
72 (62–82)
72 (62–82)
72 (62–82)
0.274
Mean age
71.03
71.32
70.35
0.281
Age
<60
155 (17.9%)
99 (16.3%)
56 (21.7%)
0.254
60–70
201 (23.2%)
145 (23.8%)
56 (21.7%)
70–80
240 (27.7%)
168 (27.6%)
72 (27.9%)
>80
270 (31.2%)
196 (32.2%)
74 (28.7%)
Sex
Female
239 (27.6%)
170 (28.0%)
69 (26.7%)
0.714
Male
627 (72.4%)
438 (72.0%)
189 (73.3%)
Race
White
735 (84.9%)
514 (84.5%)
221 (85.7%)
0.906
Black
73 (8.4%)
52 (8.6%)
21 (8.1%)
Others
58 (6.7%)
42 (6.9%)
16 (6.2%)
Marital status
Married
565 (65.2%)
394 (64.8%)
171 (66.3%)
0.730
SDW
213 (24.6%)
149 (24.5%)
64 (24.8%)
Single
88 (10.2%)
65 (10.7%)
23 (8.9%)
Grade
Grade I or Grade II
125 (14.4%)
89 (14.6%)
36 (14.0%)
0.793
Grade III or Grade IV
741 (85.6%)
519 (85.4%)
222 (86.0%)
Histology
TCC
694 (80.1%)
484 (79.6%)
210 (81.4%)
0.610
SCC
60 (6.9%)
41 (6.7%)
19 (7.4%)
Adenocarcinoma
112 (12.9%)
83 (13.7%)
29 (11.2%)
T Stage
T2
339 (39.1%)
231 (38.0%)
108 (41.9%)
0.159
T3
458 (52.9%)
322 (53.0%)
136 (52.7%)
T4
69 (8.0%)
55 (9.0%)
14 (5.4%)
N stage
N0
785 (90.6%)
550 (90.5%)
235 (91.1%)
0.773
N1 or N2 or N3
81 (9.4%)
58 (9.5%)
23 (8.9%)
M Stage
M0
835 (96.4%)
587 (96.5%)
248 (96.1%)
0.760
M1
31 (3.6%)
21 (3.5%)
10 (3.9%)
Tumor size
<3 cm
414 (47.8%)
291 (47.9%)
123 (47.7%)
0.960
>3 cm
452 (52.2%)
317 (52.1%)
135 (52.3%)
Number of tumors
Single
546 (63.0%)
391 (64.3%)
155 (60.1%)
0.238
Multiple
320 (37.0%)
217 (35.7%)
103 (39.9%)
Radiotherapy
No/unknown
760 (87.8%)
531 (87.3%)
229 (88.8%)
0.559
Yes
106 (12.2%)
77 (12.7%)
29 (11.2%)
Chemotherapy
No/unknown
588 (67.9%)
410 (67.4%)
178 (69.0%)
0.653
Yes
278 (32.1%)
198 (32.6%)
80 (31.0%)
Regional nodes examined
Non
397 (45.8%)
281 (46.2%)
116 (45.0%)
0.830
1–3
133 (15.4%)
95 (15.6%)
38 (14.7%)
>3
336 (38.8%)
232 (38.2%)
104 (40.3%)
Survival time (month)
Mean
50.76
48.63
55.78
0.033※
Median (25th–75th percentile)
38.5 (13–77.3)
37 (13–73)
41.5 (12.75–92.25)
0.123
TCC: transitional cell carcinoma, SCC: squamous cell carcinoma; other races: American Indian, Alaska Native, Asian, and Pacific Islander; SDW: separated, divorced, or widowed; ※: statistical difference.
